Altered Membrane Sodium Transport and the Presence of a Plasma Ouabain-Like Inhibitory Factor in Acute Myeloid Leukaemia

1975 ◽  
Vol 48 (3) ◽  
pp. 213-218
Author(s):  
M. Afzal Mir ◽  
H. Bobinski
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Sodium Transport ◽  
Normal Subjects ◽  
Sodium Influx ◽  
Sodium Efflux ◽  
High Sodium ◽  
Electrolyte Disturbances ◽  
Similar Factor ◽  
Acute Myeloid

1. Sodium transport studies were performed in erythrocytes from normal subjects and from patients with acute myeloid leukaemia. Sodium influx and efflux rates were increased in erythrocytes from leukaemic patients. 2. The ouabain-sensitive component of sodium efflux was increased in leukaemic erythrocytes. 3. The high sodium efflux from leukaemic erythrocytes was decreased when the incubation media contained leukaemic plasma, suggesting the presence of an ouabain-like factor in the plasma. Paired experiments failed to show the presence of a similar factor in normal plasma. 4. Leukaemic erythrocytes showed a significantly greater ouabain uptake than the normal cells. 5. The results are discussed in relation to the widespread electrolyte disturbances in acute myeloid leukaemia.

Evidence for Inhibitory and Anti-Ouabain-Like Factors in Leukaemic Blood

1981 ◽  
Vol 61 (4) ◽  
pp. 391-397 ◽  
Author(s):  
M. A. Mir
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Ringer Solution ◽  
High Dilution ◽  
Sodium Efflux ◽  
High Affinity ◽  
Electrolyte Disturbances ◽  
Plasma Factor ◽  
High Incidence ◽  
Two Factors ◽  
Acute Myeloid

1. At a high dilution in Ringer solution (1:200), leukaemic plasma significantly (P < 0.05) decreased the ouabain-sensitive and increased ouabain-insensitive components of sodium efflux from erythrocytes. At a low dilution (1:10) leukaemic plasma predominantly decreased the total and ouabain-insensitive component of sodium efflux (P < 0.01). 2. Erythrocytes from patients with leukaemia had a high affinity for the plasma factor which inhibited the total and ouabain-insensitive efflux (inhibitory factor). 3. Washings of leukaemic erythrocytes which had been incubated in leukaemic plasma contained a factor which significantly decreased the ouabain-sensitive and increased ouabain-insensitive components of sodium efflux (the anti-ouabain-like factor). 4. These studies show that leukaemic blood contains two factors which have opposite effects on sodium efflux from erythrocytes. These factors may contribute to the high incidence of multiple electrolyte disturbances in acute myeloid leukaemia.

The acute myeloid leukaemia market

2019 ◽  
Vol 19 (4) ◽  
pp. 233-234
Author(s):  
Jorrit Schaefer ◽  
Sorcha Cassidy ◽  
Rachel M. Webster
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Myeloid

Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome

2005 ◽  
Vol 44 (03) ◽  
pp. 107-117
Author(s):  
R. G. Meyer ◽  
W. Herr ◽  
A. Helisch ◽  
P. Bartenstein ◽  
I. Buchmann
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Primary Tumour ◽  
The Other ◽  
Haematopoietic Stem Cell ◽  
Other Hand ◽  
Primary Reduction ◽  
The One ◽  
Acute Myeloid

SummaryThe prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term diseasefree survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT.This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.

Sign in / Sign up

Export Citation Format

Share Document